Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,840Revenue (TTM) $M32,371Net Margin (%)50.5Altman Z-Score5.0
Enterprise Value $M107,961EPS (TTM) $11.4Operating Margin %63.0Piotroski F-Score5
P/E(ttm)7.0Beneish M-Score-2.6Pre-tax Margin (%)61.2Higher ROA y-yN
Price/Book6.610-y EBITDA Growth Rate %--Quick Ratio2.5Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %27.2Current Ratio2.7Lower Leverage y-yN
Price/Free Cash Flow6.7y-y EBITDA Growth Rate %30.6ROA % (ttm)34.1Higher Current Ratio y-yN
Dividend Yield %2.2PEG0.3ROE % (ttm)99.2Less Shares Outstanding y-yY
Payout Ratio %15.0Shares Outstanding M1,332ROIC % (ttm)82.8Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDT Rowe Price Equity Income Fund 2016-06-30 Add0.01%$78.25 - $102.29
($88.79)
$ 79.47-10%Add 1.58%1,375,000
GILDJulian Robertson 2016-03-31 Reduce-4.65%$82.71 - $101.19
($90.37)
$ 79.47-12%Reduce -90.24%38,511
GILDLeon Cooperman 2016-03-31 Buy 1.26%$82.71 - $101.19
($90.37)
$ 79.47-12%New holding516,989
GILDDavid Dreman 2016-03-31 Buy 0.24%$82.71 - $101.19
($90.37)
$ 79.47-12%New holding23,210
GILDJoel Greenblatt 2016-03-31 Add0.1%$82.71 - $101.19
($90.37)
$ 79.47-12%Add 10.68%967,642
GILDNWQ Managers 2016-03-31 Reduce-0.08%$82.71 - $101.19
($90.37)
$ 79.47-12%Reduce -30.50%116,000
GILDJohn Rogers 2016-03-31 Add0.05%$82.71 - $101.19
($90.37)
$ 79.47-12%Add 3.58%1,360,492
GILDT Rowe Price Equity Income Fund 2016-03-31 Add0.04%$82.71 - $101.19
($90.37)
$ 79.47-12%Add 8.29%1,353,600
GILDGeorge Soros 2016-03-31 Buy 0.01%$82.71 - $101.19
($90.37)
$ 79.47-12%New holding3,600
GILDKen Fisher 2016-03-31 Reduce-0.01%$82.71 - $101.19
($90.37)
$ 79.47-12%Reduce -13.63%487,030
GILDFirst Eagle Investment 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 79.47-12%Add 2200.00%9,200
GILDMario Gabelli 2016-03-31 Reduce$82.71 - $101.19
($90.37)
$ 79.47-12%Reduce -4.71%40,690
GILDRonald Muhlenkamp 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 79.47-12%Add 0.01%217,990
GILDDodge & Cox 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 79.47-12%Add 103.20%7,620
GILDT Rowe Price Equity Income Fund 2015-12-31 Buy 0.57%$97.54 - $110.96
($104.15)
$ 79.47-24%New holding1,250,000
GILDJulian Robertson 2015-12-31 Add0.55%$97.54 - $110.96
($104.19)
$ 79.47-24%Add 11.95%394,411
GILDDavid Dreman 2015-12-31 Sold Out -0.11%$97.54 - $110.96
($104.19)
$ 79.47-24%Sold Out0
GILDJohn Keeley 2015-12-31 Sold Out -0.08%$97.54 - $110.96
($104.19)
$ 79.47-24%Sold Out0
GILDJoel Greenblatt 2015-12-31 Reduce-0.06%$97.54 - $110.96
($104.19)
$ 79.47-24%Reduce -6.70%874,246
GILDKen Fisher 2015-12-31 Add$97.54 - $110.96
($104.15)
$ 79.47-24%Add 0.27%563,917
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and CEO 2016-07-05Sell112,000$84.33-5.76view
MARTIN JOHN CExecutive Chairman 2016-07-01Sell100,000$84.73-6.21view
Carter Paul RutherfordEVP Commercial Ops 2016-07-01Sell2,000$83.12-4.39view
MILLIGAN JOHN FPresident and CEO 2016-06-06Sell112,000$86.94-8.59view
MARTIN JOHN CExecutive Chairman 2016-06-01Sell100,000$86.72-8.36view
Carter Paul RutherfordEVP Commercial Ops 2016-06-01Sell2,000$87.02-8.68view
Carter Paul RutherfordEVP Commercial Ops 2016-05-31Sell57,092$86.85-8.5view
MILLIGAN JOHN FPresident and CEO 2016-05-02Sell112,000$87.71-9.39view
MARTIN JOHN CExecutive Chairman 2016-05-02Sell100,000$87.82-9.51view
Carter Paul RutherfordEVP Commercial Ops 2016-05-02Sell2,000$88.72-10.43view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
10 Most Undervalued Companies for the Enterprising Investor - July Jul 28 2016 
Gilead Sciences Is Still a Buy Jul 27 2016 
Gilead’s Valuation Makes It a Screaming Buy Jul 27 2016 
Jerome Dodson Comments on Gilead Jul 26 2016 
10 Low PE Stocks for the Enterprising Investor Jul 20 2016 
5 Best Stocks For Value Investors This Week Jul 19 2016 
An Unfair Valuation Makes a Great Investment Jul 15 2016 
My Favorite Health Care Stocks Jul 12 2016 
Gilead Sciences Insider Sells 112,000 Shares Jul 08 2016 
Stocks Have Record Quarter for Share Buybacks Jun 22 2016 

More From Other Websites
Merck posts strong 2Q numbers, while building for long term Jul 29 2016
Merck posts strong 2Q numbers, while building for long term Jul 29 2016
Amazon, Alphabet Price Targets Hiked; Ford, Gilead Downgraded Jul 29 2016
Gilead (GILD) Stock Down on Q3 Outlook, Argus Downgrades Jul 29 2016
Biotech Stocks: The End of Political Risk? Jul 29 2016
Why Key Analyst Sees More Headwinds for Gilead Sciences Jul 29 2016
Genvoya Becomes Most Prescribed Regimen for HIV Patients in US Jul 29 2016
Gilead Sciences: A Hard Wind is Gonna Blow Jul 29 2016
How Gilead Sciences’ New HIV Drugs Performed in 2Q16 Jul 29 2016
Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Dow Chemical, Ford, Gilead, Harley-Davidson,... Jul 29 2016
Morning Movers: Exxon Sinks on Earnings Miss; AbbVie Gains Jul 29 2016
Gilead Sciences downgraded by Argus Jul 29 2016
10 Most Undervalued Companies for the Enterprising Investor - July Jul 28 2016
Research Reports for Facebook, DuPont, Gilead & Others Jul 28 2016
U.S. biotech stocks win back investors in big July run Jul 28 2016
3 Big Drugmakers That Beat Wall Street Q2 Estimates Thursday Jul 28 2016
Celgene: Doing What Amgen and Gilead Couldn't Jul 28 2016
Gilead Sciences Sees Weak Sales for Its HCV Drug Internationally Jul 28 2016
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene Jul 28 2016
Gilead Sciences Seeks Growth from New HCV Patients Jul 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)